WHO has just prequalified a combination mifepristone-misoprostol (combipack) for medical abortion
A third quality assured, generic DMPA-IM contraceptive product available for procurement
New beginnings @ConceptFNDN When I started working on the heat stable carbetocin project in 2012 at the Special Programme of Research on Human Reproduction (HRP), a public private partnership between WHO/HRP, Ferring Pharmaceuticals and MSD for Mothers I was...
Concept Foundation announces A. Metin Gülmezoglu as its new Executive Director
Access to quality magnesium sulfate and implementation of guidelines can help reduce maternal deaths due to preeclampsia. When a mother dies, the impact of her death reaches much further than the individual tragedy. It affects the life and health of the family,...
WHO/UNICEF/UNFPA Joint Statement: Appropriate Storage and Management of Oxytocin – a Key Commodity for Maternal Health
Appropriate Storage and Management of Oxytocin - a Key Commodity for Maternal Health
Access to Quality Assured generic Intramuscular DMPA continues to rise
Concept Foundation is pleased to announce that over the coming year it will be working to address maternal health supply gaps in Ethiopia, with a new grant from the RHSC Innovation Fund.
Devex have recently published an opinion piece by Concept Foundation's CEO, Dr. Hans Vemer, entitled 7 Lessons on Access to Markets.
A briefing note on the quality of misoprostol products has been published in WHO Drug Information, presenting findings from the analysis of misoprostol samples from a variety of countries, specifically regarding percentage of active ingredient over time in relation to the labelled content, for products in different types of blister packs.